Читать книгу Parodontologie von A bis Z - Peter Eickholz - Страница 49

1. Caton JC, Armitage G, Berglundh T et al. A new classification scheme for periodontal and peri-implant diseases and conditions – Introduction and key changes from the 1999 classification. J Clin Periodontol 2018;45(Suppl 20):S1–S8.

2. Murakami S, Mealey BL, Mariotti A et al. Dental plaque–induced gingival conditions. J Clin Periodontol 2018; 45(Suppl 20):S17–S27.

3. Chapple ILC, Mealey BL, Van Dyke TE et al. Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol 2018;45(Suppl 20):S68–S77.

4. Sills ES, Zegarelli DJ, Hoschander MM et al. Clinical diagnosis and management of hormonally responsive oral pregnancy tumor (pyogenic granuloma). J Reprod Med 1996;41:467–470.

5. Ziskin DE, Nesse GJ. Pregnancy gingivitis. history, classification, etiology. Am J Orthod Oral Surg 1946;32:390–432.

6. Dongari-Bagtzoglou A. Drug-associated gingival enlargement. J Periodontol 2004;75:1424–1431.

7. Angelopoulous AP, Goaz PW. Incidence of diphenylhydantoin gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1972;34:898–906.

8. Barclay S, Thomason JM, Idle JR et al. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol 1992;19:311–314.

9. Nery EB, Edson RG, Lee KK et al. Prevalence of nifedipine-induced gingival hyperplasia. J Periodontol 1995;66:572–578.

10. Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol 1992;63:453–456.

11. Jorgensen MG. Prevalence of amlodipine-related gingival hyperplasia. J Periodontol 1997;68:676–678.

12. Hassel TM, Hefti AF. Drug-induced gingival overgrowth: old problem, new problem. Crit Rev Oral Biol Med 1991;2:103–137.